Signaturefd, LLC Immunovant, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 286 shares of IMVT stock, worth $7,867. This represents 0.0% of its overall portfolio holdings.

Number of Shares

286

Previous 282 1.42%

Holding current value

$7,867

Previous $7,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$27.51 - $27.51 $110 - $110	4 Added 1.42%	286 $7,000
Q1 2024 May 03, 2024	SELL	$30.27 - $43.79 $817 - $1,182	-27 Reduced 8.74%	282 $9,000
Q4 2023 Jan 31, 2024	BUY	$31.31 - $44.19 $845 - $1,193	27 Added 9.57%	309 $13,000
Q3 2023 Nov 03, 2023	BUY	$18.55 - $39.96 $2,708 - $5,834	146 Added 107.35%	282 $10,000
Q1 2023 Apr 28, 2023	BUY	$15.27 - $19.72 $122 - $157	8 Added 6.25%	136 $2,000
Q4 2022 Jan 27, 2023	BUY	$6.59 - $17.75 $843 - $2,272	128 New	128 $2,000
Q1 2022 May 02, 2022	SELL	$5.06 - $8.77 $4,250 - $7,366	-840 Closed	0 $0
Q4 2021 Jan 25, 2022	SELL	$7.33 - $9.32 $7,036 - $8,947	-960 Reduced 53.33%	840 $7,000
Q3 2021 Oct 28, 2021	BUY	$7.01 - $11.37 $2,103 - $3,410	300 Added 20.0%	1,800 $16,000
Q4 2020 Feb 11, 2021	SELL	$36.36 - $52.71 $72,720 - $105,420	-2,000 Reduced 57.14%	1,500 $69,000
Q3 2020 Nov 03, 2020	SELL	$22.61 - $38.9 $33,915 - $58,350	-1,500 Reduced 30.0%	3,500 $123,000
Q2 2020 Jul 30, 2020	BUY	$13.87 - $28.44 $20,805 - $42,660	1,500 Added 42.86%	5,000 $122,000
Q1 2020 Apr 23, 2020	BUY	$8.36 - $17.13 $29,259 - $59,955	3,500 New	3,500 $54,000

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account